Featured Stories
Steptoe Wins Runner-Up in AmLaw's 'Litigator of the Week' for Full Defense Verdict for Mead Johnson in Infant Formula Case
WASHINGTON, Sept. 5 -- Steptoe, a law firm, issued the following news release:
* * *
Steptoe Wins Runner-Up in AmLaw's "Litigator of the Week" for Full Defense Verdict for Mead Johnson in Infant Formula Case
A Steptoe team, along with their co-counsel at Covington & Burling, has been recognized as the first runner-up in The AmLaw Litigation Daily's "Litigator of the Week" for securing a full defense verdict for Mead Johnson, the maker of Enfamil infant formula.
The first bellwether trial to reach a jury verdict in the federal multidistrict litigation (MDL), Steptoe and co-counsel fought against
... Show Full Article
WASHINGTON, Sept. 5 -- Steptoe, a law firm, issued the following news release:
* * *
Steptoe Wins Runner-Up in AmLaw's "Litigator of the Week" for Full Defense Verdict for Mead Johnson in Infant Formula Case
A Steptoe team, along with their co-counsel at Covington & Burling, has been recognized as the first runner-up in The AmLaw Litigation Daily's "Litigator of the Week" for securing a full defense verdict for Mead Johnson, the maker of Enfamil infant formula.
The first bellwether trial to reach a jury verdict in the federal multidistrict litigation (MDL), Steptoe and co-counsel fought againstclaims that the cow's milk-based formula was linked to necrotizing enterocolitis (NEC) in infants. The win offers a significant signal for the hundreds of remaining bellwether and MDL cases.
For additional information on the case, please see Steptoe Helps Secure Defense Verdict for Mead Johnson in First Bellwether Trial Over Infant Formula and NEC (https://www.steptoe.com/en/news-publications/steptoe-helps-secure-defense-verdict-for-mead-johnson-in-first-bellwether-trial-over-infant-formula-and-nec.html).
The Steptoe team was led by partner Rachel Cannon, with partner Evan Glassman, of counsel George Desh, and associates Carly Rolph, Anne Wooding, Sarah Norise, and Brendan Hammond.
See Litigator of the Week Runners-Up and Shout-Outs | Law.com (https://www.law.com/litigationdaily/2026/09/04/litigator-of-the-week-runners-up-and-shout-outs/) for the story.
* * *
About Steptoe
In more than 110 years of practice, Steptoe has earned an international reputation for vigorous representation of clients and innovative thinking before governmental agencies, successful advocacy in litigation and arbitration, and creative and practical advice in structuring business transactions. Steptoe has more than 500 lawyers and other professional staff across offices in Beijing, Brussels, Chicago, Hong Kong, Houston, London, Los Angeles, New York, San Francisco, and Washington, DC. For more information, visit www.steptoe.com.
* * *
Original text here: https://www.steptoe.com/en/news-publications/steptoe-wins-runner-up-in-amlaws-litigator-of-the-week-for-full-defense-verdict-for-mead-johnson-in-infant-formula-case.html
[Category: BizLaw/Legal]
Ropes and Gray: Life Sciences and Health Care Partners Author Global Drug Pricing and Market Access Chapter in Pharmaceutical Pricing & Reimbursement 2026
BOSTON, Massachusetts, Sept. 5 -- Ropes and Gray, a law firm, issued the following news:
* * *
Life Sciences and Health Care Partners Author Global Drug Pricing and Market Access Chapter in Pharmaceutical Pricing & Reimbursement 2026
Ropes & Gray partners Lincoln Tsang, Eve Brunts and Katherine Wang co-authored the book chapter entitled "Global Drug Pricing and Market Access: The New Era of Cost Containment, Innovation, and Patient Access," in Global Legal Insights Pharmaceutical Pricing & Reimbursement 2026.
The global pharmaceutical industry stands at a pivotal crossroads, challenged to
... Show Full Article
BOSTON, Massachusetts, Sept. 5 -- Ropes and Gray, a law firm, issued the following news:
* * *
Life Sciences and Health Care Partners Author Global Drug Pricing and Market Access Chapter in Pharmaceutical Pricing & Reimbursement 2026
Ropes & Gray partners Lincoln Tsang, Eve Brunts and Katherine Wang co-authored the book chapter entitled "Global Drug Pricing and Market Access: The New Era of Cost Containment, Innovation, and Patient Access," in Global Legal Insights Pharmaceutical Pricing & Reimbursement 2026.
The global pharmaceutical industry stands at a pivotal crossroads, challenged todeliver cutting-edge therapies while ensuring affordability and broad patient access. Rapid innovation--especially in oncology, rare diseases, and chronic conditions--has transformed treatment landscapes, but the financial sustainability of health systems is under intense strain. The COVID-19 pandemic and ongoing geopolitical disruptions have exposed vulnerabilities in medicine supply chains, prompting governments and payors to prioritize supply security, diversify sourcing, and reinforce procurement frameworks. Escalating healthcare costs, aging populations, and the high prices of novel medicines are pushing policymakers to deploy a diverse arsenal of cost-containment strategies. These include direct price negotiations, international reference pricing, value-based reimbursement, and mandates for greater transparency.
Pharmaceutical companies now operate in a volatile environment where launch strategies, pricing models, and investment decisions face constant scrutiny. Risks of launch delays, product withdrawals, and market fragmentation are rising--especially in smaller or lower-priced markets. Traditional procurement models focused on lowest price are being reimagined. Today, broader value criteria--such as patient-reported outcomes and real-world effectiveness--are central to pricing and reimbursement decisions. Regulatory frameworks increasingly emphasize "most economically advantageous tender" (MEAT) criteria, balancing cost with qualitative benefits like supply resilience and patient experience.
In the United States, cost containment has become a policy centerpiece. The Most Favored Nation (MFN) pricing model and international reference pricing programs (e.g., GENEROUS, GLOBE, GUARD) benchmark US drug prices against those in other developed nations. The Inflation Reduction Act (IRA) empowers the federal government to negotiate prices for high-cost Medicare medicines, delivering substantial discounts and lowering patient out-of-pocket expenses. These reforms are reshaping global launch sequencing, as manufacturers reconsider launches in lower-priced countries to avoid price convergence. Legal challenges to US policies have failed, and new regulations targeting pharmacy benefit managers are increasing transparency and reducing patient costs. Direct-to-consumer discount models are also gaining traction, empowering patients to access affordable medicines.
Europe faces its own complexities. Fragmented pricing and reimbursement systems are under pressure from US reference pricing, leading to increased launch delays and product withdrawals. The UK has responded with a bilateral trade deal with the US, raising its cost-effectiveness threshold and capping rebate rates, though concerns persist about NHS spending and the robustness of cost-effectiveness assessments. The EU is advancing major legislative reforms--the Pharma Package, Critical Medicines Act (CMA), and EU Biotech Act--to boost competitiveness, strengthen supply chains, and incentivize local research and production. The new EU Health Technology Assessment Regulation (HTAR) introduces a Joint Clinical Assessment process, raising evidence standards and harmonizing requirements across Member States. Despite these efforts, challenges such as flat pharmaceutical spending, low venture capital investment, and threats to confidential discount mechanisms remain.
China is forging its own path, expanding access to innovative medicines through the National Healthcare Security Administration (NHSA) and the National Reimbursement Drug List (NRDL). The introduction of a new Category C for highly innovative drugs, covered by commercial insurance, reflects China's dual focus on affordability and innovation. Price negotiations and volume-based procurement continue to drive down costs but concerns about supply sustainability and investment in innovation persist.
Across all regions, the drive for pricing transparency, value-based care, and resilient supply chains is intensifying. Policymakers, payors, and industry leaders must navigate a complex web of trade-offs to ensure affordable access, reward innovation, and sustain healthcare systems. The future of global drug pricing and market access hinges on the ability of governments and industry to collaborate, adapt, and innovate in an interconnected, cost-conscious world.
* * *
Original text here: https://www.ropesgray.com/en/news-and-events/news/2026/09/life-sciences-and-health-care-partners-author-global-drug-pricing-and-market-access
[Category: BizLaw/Legal]
Ropes & Gray Advised Bain Capital in Strategic Growth Investment in RQD* Clearing
BOSTON, Massachusetts, Sept. 5 -- Ropes and Gray, a law firm, issued the following news:
* * *
Ropes & Gray Advised Bain Capital in Strategic Growth Investment in RQD* Clearing
Ropes & Gray represented Bain Capital Tech Opportunities as the lead investor in RQD* Clearing's $74 million minority growth investment. RQD/* is a clearing and custody firm providing the infrastructure that broker-dealers, RIAs, and foreign financial institutions need to access U.S. markets.
The investment was announced on Aug. 27.
Founded in 1984, Bain Capital is one of the world's leading private investment firms
... Show Full Article
BOSTON, Massachusetts, Sept. 5 -- Ropes and Gray, a law firm, issued the following news:
* * *
Ropes & Gray Advised Bain Capital in Strategic Growth Investment in RQD* Clearing
Ropes & Gray represented Bain Capital Tech Opportunities as the lead investor in RQD* Clearing's $74 million minority growth investment. RQD/* is a clearing and custody firm providing the infrastructure that broker-dealers, RIAs, and foreign financial institutions need to access U.S. markets.
The investment was announced on Aug. 27.
Founded in 1984, Bain Capital is one of the world's leading private investment firmswith 24 offices on four continents, more than 1,950 employees, and approximately $225 billion in assets under management.
Bain Capital's Tech Opportunities business aims to help growing technology companies reach their full potential.
The team was led by private capital transactions partner Elizabeth Gallucci and associate Andrea Daley and included private capital transactions partner Charlie Boer, asset management partner Brynn Rail, employment, executive compensation & benefits partner Renata Ferrari, IP transactions counsel Giancarlo Lee, and asset management associate Nathan McGuire.
* * *
Original text here: https://www.ropesgray.com/en/news-and-events/news/2026/09/ropes-gray-advised-bain-capital-in-strategic-growth-investment-in-rqd-clearing
[Category: BizLaw/Legal]
Pillsbury Secures Eleventh Circuit Victory for Aeromexico, Preserving Joint Venture With Delta Air Lines
NEW YORK, Sept. 5 -- Pillsbury, a law firm, issued the following news release:
* * *
Pillsbury Secures Eleventh Circuit Victory for Aeromexico, Preserving Joint Venture with Delta Air Lines
Pillsbury secured a major appellate victory for Aeromexico, with the U.S. Court of Appeals for the Eleventh Circuit unanimously vacating a Department of Transportation (DOT) order that would have terminated approval and antitrust immunity for the airline's long-standing joint venture with Delta Air Lines.
The nearly decade-old partnership allows Aeromexico and Delta to coordinate scheduling, pricing and
... Show Full Article
NEW YORK, Sept. 5 -- Pillsbury, a law firm, issued the following news release:
* * *
Pillsbury Secures Eleventh Circuit Victory for Aeromexico, Preserving Joint Venture with Delta Air Lines
Pillsbury secured a major appellate victory for Aeromexico, with the U.S. Court of Appeals for the Eleventh Circuit unanimously vacating a Department of Transportation (DOT) order that would have terminated approval and antitrust immunity for the airline's long-standing joint venture with Delta Air Lines.
The nearly decade-old partnership allows Aeromexico and Delta to coordinate scheduling, pricing andcapacity for flights between the U.S. and Mexico. In its published decision, the court concluded that the DOT relied on an inadequate market analysis and applied a more demanding open-skies standard to the Aeromexico-Delta joint venture than to comparable airline joint ventures.
Since the joint venture took effect in 2017, Aeromexico has transported approximately 58 million passengers on 454,000 flights between Mexico and the U.S., covering a combined 630 million miles. The ruling preserves the partnership and allows it to continue providing travelers with greater connectivity, expanded route options and lower fares. The decision also provides important guidance concerning DOT's review of international airline joint ventures.
The Pillsbury team representing Aeromexico included Aviation, Aerospace & Transportation practice group leader Charles Donley and senior counsel Edward Sauer, and Litigation partner Matthew MacLean and senior associate Nicole Steinberg, with support from Appellate partner Todd Kim.
The firm worked closely on the matter with the Gibson, Dunn & Crutcher LLP team representing Delta Air Lines, which included partners Eugene Scalia and Amir Tayrani.
* * *
Original text here: https://www.pillsburylaw.com/en/news-and-insights/pillsbury-eleventh-circuit-victory-aeromexico-joint-venture-delta-air-lines.html
[Category: BizLaw/Legal]
Hughes Hubbard Wins New York Law Journal's Law Firm of the Year
NEW YORK, Sept. 5 -- Hughes Hubbard and Reed, a law firm, issued the following news:
* * *
Hughes Hubbard Wins New York Law Journal's Law Firm of the Year
Award honors a year of landmark victories, strategic deals and pro bono excellence.
Highlights
* Firm wins New York Law Journal's 2026 Law Firm of the Year: Midsize Firms.
* Secured landmark victories in high-stakes international litigations and disputes.
* Advised on significant cross-border M&A, restructuring, finance and capital markets transactions.
-
Hughes Hubbard has won Law Firm of the Year: Midsize Firms at the New York Law
... Show Full Article
NEW YORK, Sept. 5 -- Hughes Hubbard and Reed, a law firm, issued the following news:
* * *
Hughes Hubbard Wins New York Law Journal's Law Firm of the Year
Award honors a year of landmark victories, strategic deals and pro bono excellence.
Highlights
* Firm wins New York Law Journal's 2026 Law Firm of the Year: Midsize Firms.
* Secured landmark victories in high-stakes international litigations and disputes.
* Advised on significant cross-border M&A, restructuring, finance and capital markets transactions.
-
Hughes Hubbard has won Law Firm of the Year: Midsize Firms at the New York LawJournal's 2026 New York Legal Awards. The honor recognizes the firm's outstanding work for clients, including landmark recoveries in international litigation and advising on significant cross-border deals, as well as its pro bono work.
"We are honored to receive this recognition, which reflects the trust our clients around the world place in our outstanding lawyers and business professionals to deliver exceptional results," said Neil Oxford, Chair of Hughes Hubbard.
The award reflects a year of notable successes for the firm, including major litigation victories, high-profile cross-border transactions, complex restructuring matters and impactful pro bono work.
Among the firm's most significant litigation achievements were multiple victories for Denmark's tax authority, SKAT, including a nearly $500 million jury verdict, a $165 million bench trial judgment and settlements exceeding $450 million in ongoing international tax fraud litigation.
On the transactional side, Hughes Hubbard advised clients on a range of significant domestic and cross-border matters, including Grab Holdings' acquisition of Stash Financial, Allianz X's investment in Cambridge Mobile Telematics and Flushing Financial Corp.'s merger with OceanFirst Financial Corp. The firm also counseled clients on notable capital markets, restructuring and finance transactions, including Securitize's business combination with Cantor Equity Partners II and several major airline restructurings and aircraft finance deals.
The firm's commitment to public service remained a hallmark of its practice. Hughes Hubbard lawyers represented pro bono clients in immigration, civil rights, criminal defense and housing matters, including work supporting the Peter Kreguer Clinic and other community-focused initiatives. The firm also joined the Legal Aid Society and others in filing suit against New York State over inadequate shelter allowances.
"Our success is driven by the talent and commitment of our people," said Robb Patryk, Managing Partner of Hughes Hubbard. "This recognition celebrates a year of exceptional client results, strategic growth and continued investment in the firm and our future."
The New York Legal Awards celebrate attorneys, judges and organizations whose work has made a meaningful impact on the legal profession and the communities they serve. Hughes Hubbard was honored during the publication's annual awards program in New York.
* * *
Original text here: https://www.hugheshubbard.com/news-insights/news/hughes-hubbard-wins-new-york-law-journal-s-law-firm-of-the-year
[Category: BizLaw/Legal]
Fried Frank: CVC Secondary Partners Raises $10B for Sixth Global Secondary PE Fund
NEW YORK, Sept. 5 -- Fried, Frank, Harris, Shriver and Jacobson LLP, a law firm, issued the following news release:
* * *
CVC Secondary Partners Raises $10B for Sixth Global Secondary PE Fund
Fried Frank advised CVC Secondary Partners, the dedicated secondaries investment strategy of leading global private markets manager CVC, on the final close of its sixth global secondary private equity fund Secondary Opportunities Fund VI ("SOF VI"), with aggregate capital commitments of c.$10 billion[1].
The fundraise attracted investment from a diversified and global institutional investor base of over
... Show Full Article
NEW YORK, Sept. 5 -- Fried, Frank, Harris, Shriver and Jacobson LLP, a law firm, issued the following news release:
* * *
CVC Secondary Partners Raises $10B for Sixth Global Secondary PE Fund
Fried Frank advised CVC Secondary Partners, the dedicated secondaries investment strategy of leading global private markets manager CVC, on the final close of its sixth global secondary private equity fund Secondary Opportunities Fund VI ("SOF VI"), with aggregate capital commitments of c.$10 billion[1].
The fundraise attracted investment from a diversified and global institutional investor base of over200 returning and new limited partners, with approximately 50% committed by investors that had not participated in prior Secondary Opportunity Funds ("SOF Funds").
The fundraise represents a significant increase over prior SOF Funds, underscoring the strong momentum behind CVC Secondary Partners and the continued expansion of the global private equity secondaries market. SOF VI operates in the private equity secondaries mid-market, targeting buyout fund investments managed by high-quality GPs. For more on the fundraise, read CVC's press release.
Fried Frank is proud to have advised CVC on this very significant fundraise, further strengthening our partnership and commitment to supporting CVC's strategic growth initiatives.
The Fried Frank team was led by asset management partners Kate Downey, Piers Harris and Athena Tan.
* * *
[1] Expressed in US Dollars. Taken together with parallel investment funds and accounts. Inclusive of the CVC house and employee commitments.
* * *
This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm's data policy page for further information.
* * *
URL: CVC Secondary Partners
* * *
Original text here: https://www.friedfrank.com/news-and-insights/cvc-secondary-partners-raises-10b-for-sixth-global-secondary-pe-fund-13152
[Category: BizLaw/Legal]
Dentons Advises MBank on Financing for 62.7 MW Polish Solar Portfolio
WASHINGTON, Sept. 5 -- Dentons, a law firm, issued the following news:
* * *
Dentons advises mBank on financing for 62.7 MW Polish solar portfolio
Dentons has advised mBank, acting as lender, on the financing of Project Vistula, a 62.7 MW portfolio of solar photovoltaic projects in Poland developed by London-based independent power platform Gulermak Renewables.
The PLN 152.9 million financing will support the construction and operation of five solar assets: Brodnica I and II, Glinnik I and II, and Powidz. All projects are currently under construction, with Powidz expected to be the first to
... Show Full Article
WASHINGTON, Sept. 5 -- Dentons, a law firm, issued the following news:
* * *
Dentons advises mBank on financing for 62.7 MW Polish solar portfolio
Dentons has advised mBank, acting as lender, on the financing of Project Vistula, a 62.7 MW portfolio of solar photovoltaic projects in Poland developed by London-based independent power platform Gulermak Renewables.
The PLN 152.9 million financing will support the construction and operation of five solar assets: Brodnica I and II, Glinnik I and II, and Powidz. All projects are currently under construction, with Powidz expected to be the first toenter commercial operation later this year.
The financing establishes a repeatable framework to support Gulermak Renewables' continued expansion in Poland and selected other European markets. The successful financial close is underpinned by a dual revenue structure: a government-guaranteed contract for difference providing long-term contracted revenue, complemented by a multi-site route-to-market agreement with Hekla Energy covering Brodnica and Powidz and running through to 2030.
The mBank team included Gracjan Biskup, Piotr Ziopaja and Daniel Uscimiak, while the Gulermak Renewables team included Turkekul Dogan, Zeyp Kurt, Beyza Sirkeci, Patrycja Bojdo and Menelaos Vakalopoulos.
Dentons' services were supervised by Adriana Mierzwa-Bronikowska, partner and head of the Projects practice in the Warsaw office. Managing counsel Aleksander Haleniuk led the work on the preparation, negotiation and execution of the finance documents, supported by associate Monika Niedopytala.
Managing counsel Maciej Ziolkowski led the due diligence work on the transaction, supported by associates Gracjan Bielawski, Zofia Szewczuk and Bartlomiej Ksiazek. Energy-related work was supervised by Piotr Ciolkowski, partner and co-head of the Energy and Natural Resources practice.
Senior associate Bartlomiej Slemp and associate Kacper Miller were responsible for drafting bankable EPC contracts with the general contractor and the subcontractor.
* * *
About Dentons
Redefining possibilities. Together, everywhere. For more information visit dentons.com
* * *
URL: mBank
* * *
Original text here: https://www.dentons.com/en/about-dentons/news-events-and-awards/news/2026/september/dentons-advises-mbank-on-financing-for-62-7-mw-polish-solar-portfolio
[Category: BizLaw/Legal]
